

CORRECTED  
VERSION\*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> C12N 15/12, C07K 14/47, G01N 33/50, 33/574	<b>A3</b>	<b>(11) International Publication Number:</b> WO 98/42296 <b>(43) International Publication Date:</b> 1 October 1998 (01.10.98)
<b>(21) International Application Number:</b> PCT/US98/05416 <b>(22) International Filing Date:</b> 18 March 1998 (18.03.98)  <b>(30) Priority Data:</b> 60/041,685 24 March 1997 (24.03.97) US  <b>(71) Applicant:</b> ONYX PHARMACEUTICALS, INC. [US/US]; 3031 Research Drive, Richmond, CA 94806 (US).  <b>(72) Inventors:</b> POLAKIS, Paul; 509 Barone Lane, Mill Valley, CA 94941 (US). RUBINFELD, Bonnie; 3403 Claridge Drive, Danville, CA 94526 (US).  <b>(74) Agent:</b> GIOTTA, Gregory, J.; Onyx Pharmaceuticals, Inc., 3031 Research Drive, Richmond, CA 94806 (US).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 25 March 1999 (25.03.99)	
<b>(54) Title:</b> COMPOSITIONS AND METHODS FOR DIAGNOSING/TREATING DISEASE BASED ON BETA-CATENIN/TRANSCRIPTION FACTOR INTERACTIONS		
<b>(57) Abstract</b>  Methods and compositions are described that are useful for diagnosing and/or treating disease arising from unwanted cell growth, preferably cancer, involving diagnosing cells for stabilized beta-catenin, or treating cells with compounds that disrupt or alter the formation of a complex consisting of beta-catenin/transcription factor, where the transcription factor is a member of the Lef/Tcf family.		

\*(Referred to in PCT Gazette No. 17/1999, Section II)